Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Stock Information for FibroBiologics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FibroBiologics Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Fate Therapeutics Appoints Laura Hamill to Board of Directors
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.